The purpose of this study is to evaluate whether FMT by frozen stool capsules in pediatric UC patients in remission after corticosteroid treatment, can modify their dysbiotic gut microbiota by increasing the richness of their microbiota at 6 months.
Ulcerative colitis (UC) is characterized by chronic inflammation of the colon of undetermined origin. Their incidence is increasing dramatically in the paediatric population. Pediatric-onset inflammatory bowel disease (IBD) is characterized by a greater severity than adult IBD. Although great progress has been made in recent years, the pathogenesis of IBD is not fully elucidated. During UC, an imbalance in the composition of gut microbiota, called "dysbiosis", has been identified. This dysbiosis is notably characterized by an increased proportion of pro-inflammatory microorganisms and a decreased proportion of anti-inflammatory microorganisms. The current treatments used in IBD mainly target the immune system through immunosuppressants, and help to shorten flairs and prevent recurrences, but there is no curative treatment. From a therapeutic point of view, the correction of this dysbiosis is thus an attractive approach. Until now, efficacy of microbiome-based therapies such as probiotics or antibiotics has been disappointing in IBD. Fecal microbiota transplantation (FMT) consists of the administration of fecal material from a donor into the intestinal tract of a recipient to change their microbiota composition and restore healthy conditions. FMT has been successfully used for many years for the treatment of Clostridioides difficile infection. Recent studies seem to show a benefit of FMT in UC. The investigator's main hypothesis is that the replacement of a dysbiotic microbiota by a 'healthy' microbiota by FMT can modify the richness of UC patient's microbiota and has a positive impact on the disease course. Once steroid-induced remission will be achieved, patients will be included and randomised to receive either FMT by frozen stool capsules or enemas. They will receive 3 doses at 0, 1 and 2 months. They will be followed for one year with stool samples collected every 3 months. Clinical and laboratory data will be collected.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
26
After colon cleansing using PolyEthylen glycol, the patient will have a colonoscopy under general anaesthesia. The patient will then receive orally FMT (frozen stools capsules prepared from healthy donor feces).
After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anaesthesia. The patient will then receive first FMT (frozen preparation of stools) by infusion in caecum during colonoscopy and the second and third doses by enemas.
Department of gastroenterology, Armand Trousseau Hospital
Paris, France
Department of Pediatric Gastroenterology, Hepatology and Nutrition - Necker - Enfants Malades Hospital
Paris, France
Department of Pediatric Gastroenterology, Robert Debré Hospital
Paris, France
Success of FMT with frozen stool capsules defined by an increase in the richness of the recipient's microbiota at 6 months.
Success of FMT is defined by an increase in the richness of the recipient's microbiota at 6 months. Microbiota richness will be evaluated by measuring the alpha diversity of the microbiota using Shannon index. The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the recipient microbiota at M0 and the recipient microbiota at M6.
Time frame: 6 months after the first Fecal Microbiota Transplantation (FMT)
Success of FMT with frozen stool capsules defined by an increase in the richness of the recipient's microbiota at 12 months
The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the recipient microbiota at M0 and the recipient microbiota at M12.
Time frame: 12 months after the first FMT
Success of FMT by stool enema defined by an increase in the richness of the recipient's microbiota at 6 and 12 months
The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the recipient microbiota at M0 and the recipient microbiota at M6 and M12
Time frame: 6 and 12 months after the first FMT
Success of FMT with frozen stool capsules on the change of recipient dysbiotic microbiota at 6 and 12 months
The success of the FMT will be defined by a Bray Curtis (BC) Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.
Time frame: 6 and 12 months after the first FMT
Success of FMT by enema on the change of recipient dysbiotic microbiota at 6 and 12 months
The success of the FMT will be defined by a Bray Curtis (BC) Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6 and 12 months after the first FMT
Success of FMT with frozen stool capsules on the richness and change of mucosal microbiota at 12 months
The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the mucosal recipient microbiota at M0 and the mucosal recipient microbiota at M12
Time frame: 12 months
Success of FMT by enema on the richness and change of mucosal microbiota at 12 months
The success of the FMT will be defined by an increase in the Shannon index of 0.5 points between the mucosal recipient microbiota at M0 and the mucosal recipient microbiota at M12
Time frame: 12 months
Success of FMT with frozen stool capsules on the change of mucosal recipient dysbiotic microbiota at 6 and 12 months
The success of the FMT will be defined by a Bray Curtis (BC) Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.
Time frame: 6 and 12 months after the first FMT
Success of FMT by enema on the change of mucosal recipient dysbiotic microbiota at 6 and 12 months
The success of the FMT will be defined by a Bray Curtis Index \[recipient after FMT vs donnor\] greater than a BC Index \[recipient after FMT vs recipient before FMT\], with a BC Index \[recipient after FMT vs donnor\] ≥ 0.6.
Time frame: 6 and 12 months after the first FMT
FMT with frozen stool capsules Feasibility
Number of capsules intake, facility of capsules intake, tolerance, intake duration
Time frame: At inclusion, 1 and 2 months after each FMT
FMT by enema Feasibility
Number of enemas, tolerance , enemas duration, difficulties related to the application of enemas
Time frame: At inclusion, 1 and 2 months after each FMT
Ulcerative colitis clinical relapse
Defined as a Pediatric Ulcerative Colitis Activity Index (PUCAI) \> 35, number of relapses during the follow-up, treatments received during the follow-up
Time frame: 6 and 12 months
Ulcerative colitis Endoscopic relapse
Defined as an Ulcerative Colitis Endoscopic Index of Severity (UCEIS) ≥ 2
Time frame: 12 months
Change of inflammatory blood markers from baseline to 12 months
CRP, VS, Leucocytes levels
Time frame: At inclusion, 6, 9 and 12 months
Change of faecal calprotectin from baseline to 12 months
Calprotectin level
Time frame: At inclusion, 6, 9 and 12 months
Change of patient's quality of life evaluated with IMPACT-3 questionnaire from inclusion until 12 months
IMPACT-3 questionnaire of 35 closed questions - scale ranging from 1 to 5 for all answers - higher score suggesting better quality of life
Time frame: At inclusion 2, 6, 9 and 12 months
Incidence of adverse events
Time frame: 26 months